GlobeNewswire - News from Washington

Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

Fri, 05 Feb 2021 13:00 GMT

SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design?de novo?protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the Guggenheim Healthcare Talks | 2021 Oncology Days on Friday, March 12, 2021 at 3 p.m. Eastern Time.

Avista Corp. Board Increases Common Stock Dividend

Fri, 05 Feb 2021 00:05 GMT

SPOKANE, Wash., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Avista Corp.’s (NYSE: AVA) board of directors has declared a quarterly dividend of $0.4225 per share on the company’s common stock, an increase of $0.0175 per share (4.3 percent), yielding and annualized dividend of $1.69. The common stock dividend is payable March 15, 2021, to shareholders of record at the close of business on Feb. 19, 2021.

Sana Announces Upsized Pricing of Initial Public Offering

Thu, 04 Feb 2021 04:22 GMT

SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a public offering price of $25.00 per share. All of the shares of common stock are being offered by Sana. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sana, are expected to be $587.5 million. Sana’s common stock is expected to begin trading on The Nasdaq Global Select Market on February 4, 2021, under the ticker symbol “SANA.” The offering is expected to close on February 8, 2021, subject to the satisfaction of customary closing conditions. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3,525,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, and, if exercised in full, would result in aggregate gross proceeds of approximately $675.6 million.

Miller Mendel files a patent infringement lawsuit against Washington County Sheriff’s Office for use of infringing Guardian Alliance Technologies software

Thu, 04 Feb 2021 02:50 GMT

SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- On February 1, 2021, attorneys for Miller Mendel filed a?second patent infringement lawsuit?related to use of the Guardian Alliance Technologies background investigation software.? The complaint in the most recent lawsuit, filed in Oregon Federal District Court, alleges Washington County Sheriff’s Office infringes on?Miller Mendel’s U.S. Patent 10,043,188 B2, through its use of the Guardian Alliance Technologies background investigation software. Miller Mendel believes based on records it has obtained that the?Washington County Sheriff’s Office?knew of Miller Mendel’s patent and proceeded forward nevertheless, which Miller Mendel contends constitutes willful infringement of Miller Mendel’s patent rights.

Costco Wholesale Corporation Reports January Sales Results

Wed, 03 Feb 2021 21:15 GMT

ISSAQUAH, Wash., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today reported net sales of $13.64 billion for the retail month of January, the four weeks ended January 31, 2021, an increase of 17.9 percent from $11.57 billion last year.

Atossa Therapeutics Announces Two-Year Update of?FDA-Approved Expanded Access Treatment with Endoxifen

Wed, 03 Feb 2021 14:30 GMT

SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces updated findings following 26 months of Expanded Access (or “compassionate use”) single-patient studies of Atossa’s Endoxifen.

SportsArt Announces Expansion of Its Energy Producing Fitness Equipment Line ECO-POWR with Addition of the Elite Series

Wed, 03 Feb 2021 14:00 GMT

The Elite ECO-POWR Series treadmill, elliptical and cycle offset electricity consumption in compact design

The Elite ECO-POWR Series treadmill, elliptical and cycle offset electricity consumption in compact design

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

Tue, 02 Feb 2021 21:05 GMT

SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) ?a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year of 2020 after market close on Wednesday, February 24, 2021. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Immediate Needs to Address Remote Learning Inequity for Students

Tue, 02 Feb 2021 19:39 GMT

The Washington-based Technology Alliance releases new recommendations as part of comprehensive report

The Washington-based Technology Alliance releases new recommendations as part of comprehensive report

Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early

Tue, 02 Feb 2021 14:30 GMT

SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announces that based on substantially positive results achieved with the patients enrolled to date in its Australian open-label Phase 2 clinical study of oral Endoxifen administered in the “window of opportunity” between diagnosis of breast cancer and surgery, Atossa has halted the study and is accelerating its Endoxifen program in the United States.

GREATER GOOD CHARITIES AND ACTOR CHRIS PRATT AWARD NEARLY $650,000 AFTER SUCCESSFUL FEED THY NEIGHBOR INITIATIVE TO COMBAT FOOD INSECURITY DUE TO COVID-19 PANDEMIC

Tue, 02 Feb 2021 14:21 GMT

Feed Thy Neighbor is Made Possible by The Hunger Site and 12 Tomatoes

Feed Thy Neighbor is Made Possible by The Hunger Site and 12 Tomatoes

Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria

Tue, 02 Feb 2021 13:15 GMT

CHK-336 On Track for Phase 1 Clinical Trial Initiation in the Second Half of 2021

FS Bancorp, Inc. Appoints Pamela M. Andrews to Board of Directors

Mon, 01 Feb 2021 21:05 GMT

MOUNTLAKE TERRACE, Wash., Feb. 01, 2021 (GLOBE NEWSWIRE) -- FS Bancorp, Inc. (NASDAQ:FSBW) (the “Company”), the holding company for 1st Security Bank of Washington (the “Bank”), today announced that Pamela M. Andrews has been appointed to the Board of Directors of the Company and the Bank.

Award-Winning Winemaker Charles Smith Announces New Company Name HOUSE OF SMITH

Mon, 01 Feb 2021 18:00 GMT

Seattle, WA, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Charles Smith, founder of Washington’s largest winemaker-owned winery, today announced a new name for his international company – HOUSE OF SMITH. ?A prolific winemaker, Charles is the visionary and creative force behind an extensive portfolio of celebrated wines that are now fittingly housed under his name.

Corum Client Carenity Acquired by BID Equity

Mon, 01 Feb 2021 15:00 GMT

SEATTLE, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corum announces that their client, France-based Carenity, the developer of a social platform supporting patients and caregivers, has been acquired by German Private Equity firm BID Equity. BID Equity is merging three of its portfolio companies—XClinical, Fortress Medical Systems and Carenity—creating a new data science company delivering end-to-end coverage of the clinical development process.

Rachat de Corum Client Carenity par BID Equity

Mon, 01 Feb 2021 15:00 GMT

SEATTLE (États-Unis), 01 févr. 2021 (GLOBE NEWSWIRE) -- Corum annonce que son client Carenity, développeur fran?ais d'une plateforme sociale soutenant les patients et soignants, a été racheté par le cabinet allemand de capital-investissement BID Equity. BID Equity fusionne trois de ses sociétés de portefeuille (XClinical, Fortress Medical Systems et Carenity), donnant ainsi naissance à une nouvelle entreprise spécialisée dans la science des données qui assurera une couverture de bout en bout du processus de développement clinique.

2nd Watch Taps Global Technology Services Leader to Lead Sales Organization

Mon, 01 Feb 2021 14:00 GMT

Cloud technology & digital services expert Chris Whaley tasked with expanding 2nd Watch’s sales leadership

Cloud technology & digital services expert Chris Whaley tasked with expanding 2nd Watch’s sales leadership

Change the Way You Celebrate Valentine’s Day with Papa Murphy’s HeartBaker? Pizza

Mon, 01 Feb 2021 14:00 GMT

Enjoy a Sweetheart of a Deal that includes both the beloved HeartBaker? Pizza and Chocolate Chip Cookie Dough, for a limited time

Enjoy a Sweetheart of a Deal that includes both the beloved HeartBaker? Pizza and Chocolate Chip Cookie Dough, for a limited time

Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use

Fri, 29 Jan 2021 21:01 GMT

CytoDyn will dedicate at least 200,000 vials (100,000 doses) of leronlimab from its inventory to Chiral Pharma Corp. for potential sales in the Philippines

Corum Client Leading2Lean, Manufacturing Software Platform Provider, Secures Growth Investment from M33 Growth

Fri, 29 Jan 2021 19:44 GMT

SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Corum announces today that their client, Nevada-based Leading2Lean (L2L), provider of plant floor digital production and maintenance software solutions for manufacturers, has secured a growth investment from M33 Growth.